miR-155-5p对急性髓系白血病细胞凋亡的影响及可能机制

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (4647 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of miR-155-5p on the apoptosis of acute myeloid leukemia (AML) cells and its possible mechanism. Methods: Bone marrow mononuclear cells of 43 AML patients and 21 iron deficiency anemia patients were collected, and the expression of miR1555p and Bcl2 were detected by quantitative reverse transcriptase PCR (qRT-PCR). After AML cells were transfected with miR-155-5p mimics or inhibitors, CCK8 assay was used to detect the cell activity of AML cells treated with different concentration of cytarabine, and flow cytometry was used to detect the apoptosis rate of AML cells that treated with cytarabine(0.16 μg/mL). The mRNA and protein expression levels of NF-κB and Bcl-2 in AML cells which were transfected with miR1555p inhibitor were detected by qRT-PCR and Western blotting, respectively. Results: The mRNA expression level of miR-155-5p and Bcl-2 in AML patients was significantly higher than those in anemia group. Results of CCK-8 and flow cytometry showed that AML cells transfected with miR-155-5p mimic had higher cell activity and lower apoptosis rate after treatment with cytarabine; In contrast, the cell transfected with miR-155-5p inhibitor had lower activity and higher apoptosis rate(P<0.01). The results of qRTPCR and Western blotting showed that the expression levels of NF-κB and Bcl-2 in miR-155-5p inhibitor group were decreased. Conclusion: miR1555p may inhibit AML cell apoptosis by up-regulating the expression of NF-κB and Bcl2.

Received: 03 June 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Zhi-kui1
	2
	ZHU Wei1

Cite this article:

DENG Zhi-kui1,2,ZHU Wei1.

Effect of miR-155-5p on the apoptosis of acute myeloid leukemia cells and its possible mechanism

[J]. Journal of Jiangsu University(Medicine Edition), 2020, 30(02): 138-143.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2020/V30/I02/138

［1］Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia\[J\]. Onco Targets Ther, 2019, 12: 1937-1945.

［2］Goldman SL, Hassan C, Khunte M, et al. Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity\[J\]. Front Genet, 2019, 10: 133.

［3］Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPPlike and GMPlike leukemia stem cells in acute myeloid leukemia\[J\]. Cancer Cell, 2011, 19(1): 138-152.

［4］Lai TH, Ewald B, Zecevic A, et al. HDAC inhibition induces MicroRNA182, which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia\[J\]. Clin Cancer Res, 2016, 22(14): 3537-3549.

［5］Beaumont KA, Hill DS, Daignault SM, et al. Cell cycle phasespecifc drug resistance as an escape mechanism of melanoma cells\[J\]. J Invest Dermatol, 2016,136(7):1479-1489.

［6］Li H, Hui L, Xu W. miR181a sensitizes a multidrugresistant leukemia cell line K562/A02 to daunorubicin by targeting Bcl2\[J\]. Acta BiochimBiophys Sin, 2012, 44(3): 269-277.

［7］Bayraktar R, Van Roosbroeck K. miR155 in cancer drug resistance and as target for miRNAbased therapeutics\[J\]. Cancer Metastasis Rev, 2018, 37(1): 33-44.

［8］Gerloff D, Grundler R, Wurm AA, et al. NFκB/STAT5/miR155 network targets PU.1 in FLT3ITDdriven acute myeloid leukemia\[J\]. Leukemia, 2015, 29(3): 535-547.

［9］Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B celllike and activated B celllike subtypes of diffuse large B cell lymphoma\[J\]. Int J Cancer, 2007, 121(5): 1156-1161.

［10］Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia\[J\]. Blood, 2007, 109(11): 4944-4951.

［11］Kluiver J, Poppema S, de Jong D, et al. BIC and miR155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas\[J\]. J Pathol，2005, 207(2): 243-249.

［12］Faraoni I, Laterza S, Ardiri D, et al. MiR424 and miR155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status\[J\]. J Hematol Oncol, 2012, 5: 26.

［13］Narayan N, Bracken CP, Ekert PG, et al. MicroRNA155 expression and function in AML: An evolving paradigm\[J\]. Exp Hematol, 2018, 62:1-6.